A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
This important study is looking into a new inhaled medicine called saralutinib for a serious lung condition called pulmonary arterial hypertension (PAH). PAH makes it hard for your heart to pump blood to your lungs, causing breathlessness and tiredness. In this study, some people will get the new medicine, and others will get an identical-looking dummy inhaler (placebo). No one, not even the doctors, will know who is getting what until the study ends. The main goal is to see if the new medicine helps people walk further in six minutes after 24 weeks. The study also checks for other signs of improvement and any side effects to understand if this new treatment is safe and effective.
Em resumo
Sobre o que é este estudo?
This study is about an investigational medicine called saralutinib, which is given as an inhaled powder. It's being tested for a serious condition called Pulmonary Arterial Hypertension (PAH). PAH is a rare disease where the blood vessels in your lungs become narrow, making it difficult for your heart to pump blood through them. This can lead to symptoms like shortness of breath, tiredness, and chest pain. Treating PAH is important because it can get worse over time.
The study is designed to carefully compare saralutinib with a 'placebo.' A placebo looks exactly like the real medicine but doesn't contain any active drug. Giving some people the new medicine and others the placebo helps doctors determine if any changes or improvements are truly due to the medicine itself, rather than other factors. This way, we can be sure about the medicine's effects. Neither you nor your doctor will know if you are receiving the active medicine or the placebo until the study is over.
The main thing researchers want to find out is whether saralutinib helps people with PAH improve their ability to walk. They will measure this by seeing how far people can walk in six minutes at the start of the study and again after 24 weeks. They'll also look at other important markers of health, like how long it takes for a person's condition to worsen, how many people show overall clinical improvement, and changes in certain blood tests. They will also carefully record any side effects to understand the medicine's safety. This type of study, called a Phase 3 study, is usually the last step before a new medicine might become available to the public.
Pontos principais
- Tests a new inhaled medicine (saralutinib) for PAH.
- Compares the new medicine to a dummy inhaler (placebo).
- Focuses on improving walking ability and overall health.
- Involves regular clinic visits and using an inhaler.
- Aims to check both how well it works and its safety.
Quem pode ser elegível?
To be considered for this study, you must be at least 18 years old. Both men and women are welcome to take part. Since the study focuses on Pulmonary Arterial Hypertension (PAH), you would need to have a confirmed diagnosis of this condition.
There might be other specific health requirements or conditions that would mean you can't join the study. These could include certain medications you're taking, other medical problems you have, or specific results from medical tests. These detailed rules help make sure the study is safe for everyone involved and that the results are clear.
It's important to discuss your full medical history with the study doctor and team. They will go through all the criteria to determine if this study is suitable for you. They'll also ensure you understand everything before you decide to participate.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Você tem 18 anos ou mais?
- Do you have a diagnosis of Pulmonary Arterial Hypertension (PAH)?
- Você consegue comparecer a consultas regulares na clínica?
- Are you willing to use an inhaler as part of the study?
- Are you able to participate in a six-minute walk test?
O que envolve a participação?
If you decide to take part in this study, you would primarily be using an inhaler device to take your study medicine (either saralutinib or the placebo) as directed. This would be done at home. You will have regular visits to the study clinic or hospital. These visits will involve various assessments, such as physical examinations, blood tests, and heart and lung function tests. A key assessment is the 'six-minute walk test,' where you'll walk as far as you can in six minutes, as this is how the study measures how well the medicine is working.
You will receive a supply of the study medicine (inhaler capsules) at each visit. You'll also need to keep track of any symptoms or side effects you experience. The study team will provide you with information on how to do this. There will be specific follow-up appointments to monitor your health and collect data. The overall duration of your active participation in receiving the study drug and undergoing these main assessments will be 24 weeks, though there might be some follow-up calls or visits after that period.
Riscos e benefícios potenciais
Localizações (16)
- —Não verificadoEspanha
- —Não verificadoLituânia
- —Não verificadoGrécia
- —Não verificadoFrança
- —Não verificadoDinamarca
- —Não verificadoAlemanha
- —Não verificadoBélgica
- —Não verificadoPortugal
- —Não verificadoChéquia
- —Não verificadoLetônia
- —Não verificadoPaíses Baixos
- —Não verificadoPolônia
Perguntas frequentes
What is Pulmonary Arterial Hypertension (PAH)?
PAH is a condition where the blood vessels in your lungs become narrowed, making it harder for your heart to pump blood, causing shortness of breath and tiredness.
O que é um 'placebo'?
A placebo is a dummy inhaler that looks exactly like the real medicine but contains no active drug. It helps researchers see if the real medicine is effective.
What is the 'six-minute walk test'?
It's a simple test where you walk as far as you can in six minutes. It helps doctors measure how well you can exercise and how your condition is improving.
Saberei se estou recebendo o novo medicamento ou o placebo?
No, this is a 'blinded' study, so neither you nor your doctor will know until the study is over. This ensures fair and accurate results.
Quanto tempo dura o estudo?
The main part of the study where you get the medicine and have tests will last for 24 weeks (about 6 months).
Como saber mais
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Interessado em participar?
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.